Results 41 to 50 of about 184,582 (277)

HIV-1 CRF 02 AG polymerase genes in Southern Ghana are mosaics of different 02 AG strains and the protease gene cannot infer subtypes

Virology Journal, 2009
Background Little is known about the detailed phylogeny relationships of CRF 02_AG HIV-1 polymerase genes in Ghana. The use of the protease gene of HIV-1 for subtyping has shown conflicting results. Methods The partial polymerase gene sequences of 25 HIV-
Sagoe Kwamena W, Dwidar Magda, Adiku Theophilus K, Arens Max Q   +3 more
doaj   +1 more source

Identifying transcription factors controlling the basal expression of human MRP4 highlights a substantial role for Sp1

FEBS Open Bio, EarlyView.
The MRP4 transporter exports several drugs and signaling molecules. Here, we identified key promoter elements regulating basal MRP4 expression. Using reporter assays, we defined a conserved region with essential Sp1 and contributory Ets sites, which controlled basal MRP4 expression.
Debora Singer, Angelique Kragl, Katrin Ziems, Juliane Glaubitz, Sophie Grammbauer, Susanne Hildebrandt, Mladen V. Tzvetkov, Gabriele Jedlitschky   +7 more
wiley   +1 more source

HIV-1 Protease Inhibitors From Marine Brown Alga: A Literature Review [PDF]

, 2017
The human immunodeficiency virus type 1 (HIV-1) causes an infectious disease that if left untreated can progress to acquired immunodeficiency syndrome (AIDS) and be fatal.
Nunez Aguilar, Eric
core   +1 more source

The AFF4 scaffold binds human P-TEFb adjacent to HIV Tat. [PDF]

, 2013
Human positive transcription elongation factor b (P-TEFb) phosphorylates RNA polymerase II and regulatory proteins to trigger elongation of many gene transcripts.
Alber, Tom, Bao, Katherine, Birnberg, Andrew, Chou, Seemay, Krogan, Nevan J, Schulze-Gahmen, Ursula, Upton, Heather, Zhou, Qiang   +7 more
core   +1 more source

HIV-1 Protease Inhibitors [PDF]

Clinical Infectious Diseases, 2000
Treatment of human immunodeficiency virus type 1 (HIV-1) infection with regimens that include protease inhibitors (PIs) has contributed to marked improvements in HIV-related disease progression and mortality. Five PIs are approved by the US Food and Drug Administration and have potent activity in vitro.
openaire   +2 more sources

Strategies for Loading and Releasing Peptide Therapeutics in Biodegradable Carriers

Advanced Functional Materials, EarlyView.
A biodegradable carrier‐based peptide delivery system is a powerful treatment platform for diverse diseases, owing to its superior therapeutic efficacy and low toxicity. This review examines the conventional peptide‐loaded carrier fabrication process and its current limitations.
Wookyoung Jang, Ki Wan Bong
wiley   +1 more source

Enhanced Human Antigen‐Specific B Cell Responses Using In Vitro 3D Tonsil Cultures Containing Stromal Cells

Advanced Healthcare Materials, EarlyView.
We developed a fully human 3D tonsil cell culture system incorporating supportive stromal cells that better sustains and activates immune cells than conventional methods. The model generates stronger, more targeted antibody responses to viral antigens and vaccines, providing a physiologically relevant and entirely human platform for studying immune ...
Maaike V. J. Braham, Marlon de Gast, Liubov Babii, Sabine Kruijer, Theo M. Bestebroer, Mathilde Richard, Mathieu Claireaux, S. Marieke van Ham, Jelle de Wit, Cécile A. C. M. van Els, Anja ten Brinke, Marit J. van Gils   +11 more
wiley   +1 more source

Minor mutations in HIV protease at baseline and appearance of primary mutation 90M in patients for whom their first protease-inhibitor ntiretroviral regimens failed [PDF]

, 2004
The association between minor mutations in human immunodeficiency virus (HIV) protease at baseline and development of common primary mutation 90M at virological failure (conferring some resistance to all protease inhibitors [PIs]) was evaluated in 93
Antonella, D'Arminio Monforte, Balotta, Claudio, Bertoli, Ada, Cadeo, Giampiero, Chirianni, Antonio, Cozzi-Lepri, Alessandro, De Stefano, Carlo, Forbici, Federica, Mura, Maria Stella Anna, Orani, Anna, Perno, Carlo Federico, Violin, Michela   +11 more
core  

Low lopinavir plasma or hair concentrations explain second-line protease inhibitor failures in a resource-limited setting. [PDF]

, 2011
In resource-limited settings, many patients, with no prior protease inhibitor (PI) treatment on a second-line, high genetic barrier, ritonavir-boosted PI-containing regimen have virologic ...
Arribas, Bangsberg, Barreiro, Berg, Carolina Malavazzi, Cassani, Delaugerre, El-Khatib, Eric Decloedt, Frost, Gandhi, Gardner, Gary Maartens, Gathe, Gert Uves van Zyl, Helen McIlleron, Huang, Jean B Nachega, Kosuge, Lize van der Merwe, Michele Zeier, Mo, Monica Gandhi, Peter Smith, Pujades-Rodriguez, Quiros-Roldan, Riddler, Thijs E van Mens, van Zyl, van Zyl, Yong Huang   +30 more
core   +3 more sources

HIV protease inhibitors and atherosclerosis [PDF]

Journal of Clinical Investigation, 2003
The advent of highly active antiretroviral therapy (HAART), including the use of HIV protease inhibitors (PIs) has significantly reduced the morbidity and mortality of AIDS in HIV infected patients. Unfortunately, the adverse effects of PIs, including dyslipidemia, lipodystrophy, insulin resistance, and premature atherosclerosis, are cause for concern ...
openaire   +2 more sources